Using PARP Inhibitors in Frontline Maintenance Therapy for Ovarian Cancer.

Abstract

Ovarian cancer is the leading cause of mortality among gynecologic cancers in the United States, expected to result in roughly 13,940 deaths in 2020. Between 2008 and 2017, mortality decreased by 2.3% per year. Incidence rates also decreased, with a 1.6% drop per year from 2007 to 2016. In 2020, an estimated 21,750 new cases of ovarian cancer will be diagnosed. The majority (90%) of ovarian cancers are epithelial ovarian cancer-often high-grade serous adenomas, which are associated with a poor prognosis and have the fewest known risk factors.